Evolent Health (NYSE:EVH) Shares Climb 11.5% – Here’s What Happened

Evolent Health, Inc (NYSE:EVH) rose 11.5% during trading on Wednesday. The company traded as high as $4.73 and last traded at $4.7960. 228,867 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 2,828,374 shares. The stock had previously closed at $4.30.

Evolent Health News Roundup

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Oppenheimer raised its price target to $7 from $6 and maintained an “outperform” rating, signaling greater confidence in Evolent’s prospects. Oppenheimer recommendations
• Positive Sentiment: Needham & Company lifted its target to $6 from $5 and upgraded its rating to “buy,” adding to the favorable analyst outlook. Needham recommendations
• Positive Sentiment: Third-quarter adjusted earnings of $0.06 per share matched consensus and improved from $0.05 a year earlier. Revenue grew 51.3% year over year to $725.37 million. Evolent third-quarter results
• Positive Sentiment: For fiscal 2026, Evolent guided to revenue of $2.6 billion–$2.7 billion, with the top of the range above the $2.6 billion consensus estimate.
• Neutral Sentiment: Quarterly revenue was modestly below analysts’ $727.06 million estimate, despite the substantial year-over-year increase. Quarterly results compared with estimates
• Negative Sentiment: The company continued to report a negative net margin and negative return on equity, underscoring ongoing profitability challenges.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Truist Financial dropped their price target on Evolent Health from $7.00 to $6.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. Needham & Company LLC boosted their price objective on Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity Group decreased their price objective on Evolent Health from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, August 10th. Weiss Ratings downgraded Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Finally, JPMorgan Chase & Co. raised their target price on shares of Evolent Health from $5.00 to $6.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 18th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.11.

Evolent Health Price Performance

The stock’s fifty day moving average price is $4.17 and its 200-day moving average price is $3.88. The company has a debt-to-equity ratio of 2.52, a quick ratio of 1.24 and a current ratio of 1.24. The firm has a market cap of $518.38 million, a PE ratio of -1.00 and a beta of 1.03.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, November 5th. The technology company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The company had revenue of $725.37 million for the quarter, compared to the consensus estimate of $727.06 million. Evolent Health had a negative return on equity of 4.27% and a negative net margin of 24.08%. Evolent Health’s quarterly revenue was up 51.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 earnings per share. As a group, equities analysts forecast that Evolent Health, Inc will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling at Evolent Health

In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total transaction of $329,460.00. Following the completion of the transaction, the president directly owned 655,133 shares of the company’s stock, valued at $3,275,665. The trade was a 9.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Maverick Capital Ltd. raised its stake in shares of Evolent Health by 1.3% in the 1st quarter. Maverick Capital Ltd. now owns 2,572,763 shares of the technology company’s stock worth $5,866,000 after buying an additional 32,833 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Evolent Health by 72.2% during the third quarter. Russell Investments Group Ltd. now owns 350,127 shares of the technology company’s stock valued at $1,222,000 after buying an additional 146,758 shares in the last quarter. Congress Asset Management Co. boosted its stake in Evolent Health by 20.3% during the third quarter. Congress Asset Management Co. now owns 275,158 shares of the technology company’s stock valued at $960,000 after buying an additional 46,466 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Evolent Health during the second quarter valued at about $760,000. Finally, Sei Investments Co. grew its holdings in Evolent Health by 50.8% during the first quarter. Sei Investments Co. now owns 302,281 shares of the technology company’s stock worth $689,000 after acquiring an additional 101,867 shares during the period.

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.